Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (220)	2/1/2000 1:44:00 PM
From: thebeach	Read Replies (1) \| Respond to of 356

More news for PBP holders: disclaimer FOR FURTHER INFORMATION PLEASE CONTACT: Procyon BioPharma Inc. Hans J. Mader President and CEO (514) 685-9283 E-mail: hmader@procyonbiopharma.com Web site: www.procyonbiopharma.com or NATIONAL Public Relations Nathalie Bourque (514) 843-2309 -------------------------------------------------------------------------------- NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS FOR: PROCYON BIOPHARMA INC. CDNX SYMBOL: PBP FEBRUARY 1, 2000 Option for Additional 200,000 Shares of Procyon Biopharma Inc. Exercised by Yorkton Securities MONTREAL, QUEBEC--Procyon BioPharma Inc. ("Procyon") announced today that Yorkton Securities has exercised its final option to acquire an additional 200,000 common shares of Procyon. Yorkton had already exercised an option on 100,000 shares in December, 1999. Employees, directors and other shareholders also recently exercised options for additional shares bringing to approximately $500,000 the total proceeds to the Company. "The decision by Yorkton to fully exercise all its options to acquire additional common shares of Procyon Biopharma demonstrates the Company's confidence in the potential of Procyon's technologies and pipeline," stated Hans J. Mader, Procyon's President and CEO. "They have been with us from the very beginning; they know us well and we sincerely appreciate their support." Procyon announced in November that it had completed a private placement of $3 million subscribed by directors, employees, shareholders and new investors including Quebec-based venture capital firms, T2C2 and Innovatech du Grand Montreal, as well as European sources. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to diagnose and treat cancer. Procyon's Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. In addition, the estimation of PSP94 levels in prostate cancer patients may have prognostic and diagnostic applications. Procyon also has two late-stage products: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the CDNX under the ticker symbol, PBP. The CDNX has neither approved nor disapproved the information contained in this release.